[go: up one dir, main page]

NO20071658L - Alkil-pyridiner som 11-beta-inhibitorer for diabetes - Google Patents

Alkil-pyridiner som 11-beta-inhibitorer for diabetes

Info

Publication number
NO20071658L
NO20071658L NO20071658A NO20071658A NO20071658L NO 20071658 L NO20071658 L NO 20071658L NO 20071658 A NO20071658 A NO 20071658A NO 20071658 A NO20071658 A NO 20071658A NO 20071658 L NO20071658 L NO 20071658L
Authority
NO
Norway
Prior art keywords
diabetes
beta inhibitors
alkyl pyridines
pyridines
alkyl
Prior art date
Application number
NO20071658A
Other languages
English (en)
Inventor
Werner Neidhart
Bernd Kuhn
Alexander Mayweg
Kurt Amrein
Daniel Hunziker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35276680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071658(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20071658L publication Critical patent/NO20071658L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

110 Forbindelser med formel så vel som farmasøytisk akseptable salter og estere derav, hvor R1 til R6 har betydningen gitt i krav 1, kan anvendes i form av farmasøytiske preparater.
NO20071658A 2004-10-04 2007-03-29 Alkil-pyridiner som 11-beta-inhibitorer for diabetes NO20071658L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104856 2004-10-04
PCT/EP2005/010372 WO2006037501A1 (en) 2004-10-04 2005-09-26 Alkil-pyridines as 11-beta inhibitors for diabetes

Publications (1)

Publication Number Publication Date
NO20071658L true NO20071658L (no) 2007-05-03

Family

ID=35276680

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071658A NO20071658L (no) 2004-10-04 2007-03-29 Alkil-pyridiner som 11-beta-inhibitorer for diabetes

Country Status (18)

Country Link
US (1) US7482341B2 (no)
EP (1) EP1799647A1 (no)
JP (2) JP5414990B2 (no)
KR (1) KR100874313B1 (no)
CN (1) CN101035762B (no)
AR (1) AR054688A1 (no)
AU (1) AU2005291561B2 (no)
BR (1) BRPI0516454A (no)
CA (1) CA2582276C (no)
IL (1) IL182310A0 (no)
MX (1) MX2007003913A (no)
MY (1) MY139522A (no)
NO (1) NO20071658L (no)
NZ (1) NZ554014A (no)
RU (1) RU2383533C2 (no)
TW (1) TWI298721B (no)
WO (1) WO2006037501A1 (no)
ZA (1) ZA200702716B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582276C (en) * 2004-10-04 2011-09-13 F. Hoffmann-La Roche Ag Alkil-pyridines as 11-beta inhibitors for diabetes
WO2006106423A2 (en) * 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
AU2006244206A1 (en) * 2005-05-10 2006-11-16 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
JP4250675B2 (ja) * 2005-06-16 2009-04-08 ファイザー・インク Ｎ−（ピリジン−２−イル）−スルホンアミド誘導体
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2663901A1 (en) * 2006-09-21 2008-03-27 Piramal Life Sciences Limited Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
EP2190432A2 (en) * 2007-08-22 2010-06-02 Protelogiecs, Ltd. Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors
CA2730499A1 (en) * 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
US20130158035A1 (en) * 2010-08-24 2013-06-20 Brigham Young University Antimetastatic compounds
WO2012124744A1 (ja) * 2011-03-14 2012-09-20 大正製薬株式会社 含窒素縮合複素環化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
CN104974084A (zh) * 2015-07-19 2015-10-14 佛山市赛维斯医药科技有限公司 一类胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
RU2652993C1 (ru) * 2017-06-07 2018-05-04 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Новое 2-стирилпроизводное 4-(2,6-диметил-4-оксо-5-фенил-4н-пиримидин-1-ил)-бензсульфамида, обладающее эндотелеопротекторной активностью
US20230183203A1 (en) * 2020-05-27 2023-06-15 The Penn State Research Foundation Antibacterial compounds
TWI884348B (zh) * 2021-01-06 2025-05-21 日商中外製藥股份有限公司 酸性官能基的烷基化方法
WO2022266794A1 (zh) * 2021-06-21 2022-12-29 武汉睿健医药科技有限公司 Oct4高选择性活化剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT673937E (pt) * 1993-09-10 2004-04-30 Eisai Co Ltd Derivados biciclicos heterociclicos de sulfonamida e de ester sulfonico
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
MXPA04004837A (es) * 2001-11-22 2004-08-02 Biovitrum Ab Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
WO2003044000A1 (en) * 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
DE602004017703D1 (de) * 2003-02-24 2008-12-24 Arena Pharm Inc Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus
EP1679309A4 (en) * 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
BRPI0417687A (pt) * 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
CN1897944A (zh) * 2003-12-19 2007-01-17 辉瑞有限公司 用于治疗糖尿病和肥胖症的11－β－羟基类固醇脱氢酶－1型(11－β－HSD－1 ) 抑制剂苯磺酰胺基－吡啶－2－基衍生物和相关化合物
CA2582276C (en) * 2004-10-04 2011-09-13 F. Hoffmann-La Roche Ag Alkil-pyridines as 11-beta inhibitors for diabetes

Also Published As

Publication number Publication date
JP2008515826A (ja) 2008-05-15
MY139522A (en) 2009-10-30
ZA200702716B (en) 2008-07-30
TWI298721B (en) 2008-07-11
AU2005291561A1 (en) 2006-04-13
AR054688A1 (es) 2007-07-11
CA2582276C (en) 2011-09-13
CA2582276A1 (en) 2006-04-13
RU2383533C2 (ru) 2010-03-10
AU2005291561B2 (en) 2010-02-25
US7482341B2 (en) 2009-01-27
MX2007003913A (es) 2007-05-21
JP5414990B2 (ja) 2014-02-12
IL182310A0 (en) 2007-07-24
EP1799647A1 (en) 2007-06-27
KR100874313B1 (ko) 2008-12-18
KR20070063527A (ko) 2007-06-19
WO2006037501A9 (en) 2007-08-02
JP5351199B2 (ja) 2013-11-27
US20060074237A1 (en) 2006-04-06
TW200616958A (en) 2006-06-01
JP2011157373A (ja) 2011-08-18
NZ554014A (en) 2010-06-25
RU2007116431A (ru) 2008-11-10
BRPI0516454A (pt) 2008-09-02
CN101035762B (zh) 2010-09-29
CN101035762A (zh) 2007-09-12
WO2006037501A1 (en) 2006-04-13
HK1108283A1 (zh) 2008-05-02

Similar Documents

Publication Publication Date Title
NO20071658L (no) Alkil-pyridiner som 11-beta-inhibitorer for diabetes
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20080554L (no) Pyrazolonderivater
NO20070445L (no) Pyrimidinderivater.
NO20070458L (no) Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20054852L (no) GFAT inhibitorer
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
NO20085121L (no) Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme
MX2012000414A (es) Derivados piridin-4-ilo.
NO20072756L (no) 4-(4-(imidazol)-4-yl)-pyrimidin-2-ylamino)benzamider som CDK-inhibitorer
NO20082561L (no) Nye koblede pyrrolderivater
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
NO20066055L (no) Pyridinderivater
MY149853A (en) Pyridin-4-yl derivatives as immunomodulating agents
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NO20064077L (no) Kemokinreseptorantagonister
MX2010005824A (es) Derivados de aminotiazol.
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application